GlassScriptPhysician profile
Samuel Waling
NPI 1053774018
$3,048.42
in general payments reported to CMS, 2019-2025
21 companies · $769 in 2025
The $769 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $118 · 2020: $362 · 2021: $342 · 2022: $597 · 2023: $708 · 2024: $154 · 2025: $769.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,630.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,630.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $630.33 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $616.32 | 2020-2023 | Trelegy Ellipta, Shingrix |
| Lilly USA, LLC | $446.56 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Astrazeneca Pharmaceuticals LP | $322.48 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $156.41 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $108.83 | 2022-2023 | |
| Abbott Laboratories | $102.14 | 2023-2025 | Freestyle Libre 3 |
| Amgen INC. | $98.21 | 2024-2025 | Repatha, Repatha, Otezla |
| Merck Sharp & Dohme LLC | $94.68 | 2022-2023 | Verquvo, Belsomra, Steglatro |
| Exact Sciences Corporation | $78.02 | 2025 | The Cologuard Plus Collection Kit |
| Janssen Pharmaceuticals, INC | $57.50 | 2021-2022 | |
| Dexcom, INC. | $56.04 | 2025 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $54.21 | 2020-2025 | |
| Sanofi Pasteur INC. | $37.41 | 2023 | |
| Astellas Pharma US INC | $36.82 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $33.90 | 2023-2025 | Xifaxan |
| Corium, LLC | $33.48 | 2024 | Azstarys |
| Idorsia Pharmaceuticals US INC | $24.91 | 2022-2023 | Quviviq |
| Novavax INC | $23.63 | 2023 | Novavax Covid-19 Vaccine, Adjuvanted |
| Ibsa Pharma INC. | $22.99 | 2025 | Licart, Flector, Tirosint |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.55 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Waling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.